Changes in surface expression of N-methyl- D-aspartate receptors in the striatum in a rat model of Parkinson's disease

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 165-173

  Gan, Jing ^a   Qi, Chen ^a   Mao, Li Min ^b   Liu, Zhenguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; Caudate putamen; Dopamine; Excitatory amino acid; GluN; Glutamate; NMDA; Nucleus accumbens

Indexed keywords

DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; OXIDOPAMINE; NR1 NMDA RECEPTOR; NR2B NMDA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN LEVEL; CATECHOLAMINE DEPLETION; CELL ISOLATION; CELL LEVEL; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE DEPLETION; DOPAMINERGIC SYSTEM; MALE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SUBUNIT; RAT; ANIMAL; CHEMISTRY; METABOLISM; PARKINSONISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CORPUS STRIATUM; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84892702537     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S51559     Document Type: Article

References (33)

1. Traynelis SF, Wollmuth LP, McBain CJ, etal. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405-496.
2. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7-61.
3. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005;179(1):4-29.
4. Standaert DG, Testa CM, Young AB, Penney JB. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol. 1994;343(1):1-16.
5. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther. 2003;97(1):55-85.
6. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. Synapse. 1998;30(2):227-235.
7. Zavitsanou K, Mitsacos A, Giompres P, Kouvelas ED. Changes in [3H]AMPA and [3H]kainate binding in rat caudate-putamen and nucleus accumbens after 6-hydroxydopamine lesions of the medial forebrain bundle: an autoradiographic study. Brain Res. 1996;731(1-2):132-140.
8. Lai SK, Tse YC, Yang MS, Wong CK, Chan YS, Yung KK. Gene expression of glutamate receptors GluR1 and NR1 is differentially modulated in striatal neurons in rats after 6-hydroxydopamine lesion. Neurochem Int. 2003;43(7):639-653.
9. Nandhu MS, Paul J, Kuruvila KP, Abraham PM, Antony S, Paulose CS. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA. Mol Cell Biochem. 2011;353(1-2):47-57.
10. Ng OT, Chen LW, Chan YS, Yung KK. Small interfering RNA specific for N-methyl-D-aspartate receptor 2B offers neuroprotection to dopamine neurons through activation of MAP kinase. Neurosignals. 2013;21(1-2):42-54.
11. Dunah AW, Wang YH, Yasuda RP, etal. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol. 2000;57(2):342-352.
12. Gardoni F, Picconi B, Ghiglieri V, etal. A critical int eraction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci. 2006;26(11):2914-2922.
13. Kong M, Ba M, Song L, Liu Z. Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum. Neurochem Res. 2009;34(8):1513-1521.
14. Fiorentini C, Rizzetti MC, Busi C, etal. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol. 2006;69(3):805-812.
15. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. London, UK: Academic Press/Elsevier; 2007.
16. Ye M, Wang XJ, Zhang YH, etal. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Res. 2007;1142:206-216.
17. Wang XJ, Liu WG, Zhang YH, Lu GQ, Chen SD. Effect of transplantation of c17.2 cells transfected with interleukin-10 gene on intracerebral immune response in rat model of Parkinson's disease. Neurosci Lett. 2007;423(2):95-99.
18. Mao LM, Wang W, Chu XP, etal. Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat Neurosci. 2009;12(5):602-610.
19. Boudreau AC, Milovanovic M, Conrad KL, Nelson C, Ferrario CR, Wolf ME. A protein cross-linking assay for measuring cell surface expression of glutamate receptor subunits in the rodent brain after in vivo treatments. Curr Protoc Neurosci. 2012;Chapter 5:Unit 5.30.1-Unit 5.3019.
20. Carino C, Fibuch EE, Mao LM, Wang JQ. Dynamic loss of surface-expressed AMPA receptors in mouse cortical and striatal neurons during anesthesia. J Neurosci Res. 2012;90(1):315-323.
21. Boudreau AC, Wolf ME. Behavioral sensitization to cocaine is associated with increased AMPA receptor surface expression in the nucleus accumbens. J Neurosci. 2005;25(40):9144-9151.
22. Blandini F, Armentero MT, Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord. 2008;14 Suppl 2: S124-S129.
23. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res. 2007;11(3-4):151-167.
24. Wang YT, Salter MW. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature. 1994;369(6477):233-235.
25. Truong L, Allbutt HN, Coster MJ, Kassiou M, Henderson JM. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Res Bull. 2009;78(2-3):91-96.
26. Rao VL, Bowen KK, Dempsey RJ. Transient focal cerebral ischemia down-regulates glutamate transporters GLT-1 and EAAC1 expression in rat brain. Neurochem Res. 2001;26(5):497-502.
27. Nandhu MS, Paul J, Kuruvilla KP, Malat A, Romeo C, Paulose CS. Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation. J Biomed Sci. 2011;18:5.
28. Löschmann PA, De Groote C, Smith L, etal. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004;187(1):86-93.
29. Liu Y, Wong TP, Aarts M, etal. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007;27(11):2846-2857.
30. Lai SK, Ng TK, Lau WK, etal. Selective knockdown of gene expression of N-methyl-D-aspartate receptor one ameliorates Parkinsonian motor symptom in 6-hydroxydopamine-lesioned rats. Neurochem Int. 2004;45(1):11-22.
31. Sze SC, Wong CK, Yung KK. Modulation of the gene expression of N-methyl-D-aspartate receptor NR2B subunit in the rat neostriatum by a single dose of specific antisense oligodeoxynucleotide. Neurochem Int. 2001;39(4):319-327.
32. Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets. 2009;8(6):475-491.
33. Addy C, Assaid C, Hreniuk D, etal. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol. 2009;49(7):856-864.